Evidence map›Paper›PMID 36672182›Full record

ArticleCells2023

A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2

Andreas A Hombach, Christine Ambrose, Roy Lobb, Paul Rennert, Hinrich Abken

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. The Current Landscape of Modular CAR T Cells.International journal of molecular sciences · 2025
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Andreas A HombachDepartment I Internal Medicine, University Hospital Cologne, Robert-Koch-Str. 21, 50931 Köln, Germany.
Christine AmbroseAleta Biotherapeutics Inc., Natick, MA 01760, USA.
Roy LobbAleta Biotherapeutics Inc., Natick, MA 01760, USA.
Paul RennertAleta Biotherapeutics Inc., Natick, MA 01760, USA.ORCID 0000-0002-4573-3764
Hinrich AbkenLeibniz Institute for Immunotherapy, Division Genetic Immunotherapy, University Regensburg, 93053 Regensburg, Germany.ORCID 0000-0002-4302-3240
Leibniz Institute for ImmunotherapyUniversity Hospital Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of CD19-specific CAR T cells in the treatment of leukemia/lymphoma relies, at least in part, on the unique properties of the particular CAR and the presence of healthy B cells that enhance the target cell lysis and cytokine secretion through repetitive stimulation. Here, we report to apply the same CAR to target solid tumors, such as ErbB2

Indexed as

NeoplasmsAdaptor Proteins, Signal TransducingB-LymphocytesErb-b2 Receptor Tyrosine KinasesHumansT-LymphocytesTrastuzumabAdaptor Proteins, Signal TransducingERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabCD19chimeric antigen receptorErbB2 (Her2/neu)herceptinscFv fusion protein

Identifiers

PMID36672182
PMCPMC9856536
OpenAlexW4313825983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.